Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Discovery Platform
Sponsor : Vividion Therapeutics
Deal Size : $448.0 million
Deal Type : Collaboration
Tavros Therapeutics Achieves Two Milestone Payments in Collaboration with Vividion
Details : The collaboration aims to deliver novel precision therapeutics capable of addressing cancer-causing proteins that have eluded traditional small molecule drugs.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : $17.5 million
May 14, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Discovery Platform
Sponsor : Vividion Therapeutics
Deal Size : $448.0 million
Deal Type : Collaboration
Tavros Therapeutics and OpenBench Expand Strategic Collaboration for Small Molecule Drug Discovery
Details : The multi-target collaboration leverages Tavros’ proprietary functional genomic discovery program and OpenBench’s AI-enabled screening platform to discover small molecule modulators of up to five oncology targets across an initial 18-month term.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
April 27, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Discovery
Sponsor : Vividion Therapeutics
Deal Size : $448.0 million
Deal Type : Collaboration
Details : Tavros leverages its functional and computational genomics technologies to uncover unique vulnerabilities within tumors to discover novel targets and biomarkers in areas of high unmet clinical need and identify novel clinical positioning strategies for e...
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : $17.5 million
October 12, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Discovery
Sponsor : Vividion Therapeutics
Deal Size : $448.0 million
Deal Type : Collaboration
LOOKING FOR A SUPPLIER?